Inhibrx Biosciences Ratios (2023-2025) | INBX

Ratios Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
EBT Margin -287,741.18%-43,518.49%-5,628.76%968.14%-34,657.96%-47,865.00%1,610.67%912.19%1,108.33%
EBIT Margin -257,447.06%-38,510.08%-5,403.24%908.06%3,001.27%-49,928.00%1,595.43%871.98%1,062.94%
EBITDA Margin -257,447.06%-38,510.08%-5,403.24%908.06%3,001.27%-49,928.00%1,595.43%871.98%1,062.94%
Operating Margin -257,447.06%-38,510.08%-5,403.24%908.06%3,001.27%-49,928.00%1,595.43%871.98%1,062.94%
Net Margin -287,741.18%-43,520.17%-5,628.52%968.14%-34,657.92%-47,865.00%1,610.67%912.26%1,108.33%
FCF Margin -46,062.18%-3,688.07%789.29%1,092.58%-43,736.00%1,335.66%953.61%1,063.63%
Efficiency
Assets Average 240.49M201.66M211.70M227.38M194.79M
Equity Average 198.92M156.03M114.01M81.50M52.69M
Invested Capital 43.50M219.37M178.47M133.58M193.10M167.84M136.75M
Asset Utilization Ratio -0.06-0.08-0.05-0.05
Leverage & Solvency
Interest Coverage Ratio -5.79-5.62-10.74-9.08-30.01-15.95-8.72-10.63
Debt to Equity 4.761.041.452.71
Debt Ratio 0.670.410.470.56
Equity Ratio 0.140.850.800.740.390.320.21
Times Interest Earned -5.79-5.62-10.74-9.08-30.01-15.95-8.72-10.63
Valuation
Enterprise Value -277.92M-37.29M30.36M70.33M-14.00M19.97M334.77M
Market Capitalization 189.61M226.69M222.93M202.52M206.57M487.87M
Return Ratios
Return on Sales 42.67%-139.34%-143.54%-107.15%14.76%17.40%
Return on Capital Employed -1.88%-2.06%-1.79%-0.89%-0.97%
Return on Assets 6.83%8.37%8.14%-0.72%-0.80%
Return on Equity 8.26%10.82%15.11%-2.01%-2.94%